-
ESMO 2025 preview: Key late-breaking abstracts in genitourinary oncology
25 Sep 2025 19:28 GMT
As the final quarter of 2025 comes into view, the calendar is filling with important scientific gatherings that will shape the next wave of urology practice and research. Among these, the European Society for Medical Oncology (ESMO) Congress has become one …
-
ASCO 2025: Johnson & Johnson’s Akeega set to be first PARP therapy for mCSPC
04 Jun 2025 11:30 GMT
At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the randomised, double-blind, placebo-controlled Phase III AMPLITUDE (NCT04497844) clinical …
-
Johnson & Johnson Reports Q1 2025 Results
15 Apr 2025 10:39 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 …
-
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
22 Jan 2025 11:31 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in …
-
Donald Trump's big pharma win as Labour life sciences agenda is disappearing, says ALEX BRUMMER
19 Sep 2025 21:09 GMT
By ALEX BRUMMER, CONSULTANT EDITOR
Updated: 16:50 EDT, 19 September 2025
Here is a bizarre outcome from Donald Trump's State Visit: Britain's leading-edge big pharma companies AstraZeneca and GSK are pledging £59billion of investment in the US over …
-
Johnson & Johnson Reports Q3 2024 Results
15 Oct 2024 10:25 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” …
-
Johnson & Johnson reports Q2 2024 results
17 Jul 2024 12:05 GMT
Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and …
-
<![CDATA[Navigating ARANOTE Trial Findings and Insurance for Prostate Cancer]]>
16 Sep 2025 01:00 GMT
Darolutamide (Nubeqa) is an androgen receptor inhibitor that, when combined with androgen-deprivation therapy (ADT), has demonstrated significant efficacy in treating metastatic hormone-sensitive prostate cancer (mHSPC). Tian Zhang, MD, MHS, an associate …
-
Johnson & Johnson Executive Vice President William N Hait to retire
01 Jun 2024 11:14 GMT
New Brunswick: Johnson & Johnson has announced that William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September of this year.
Since joining Johnson & …
-
Johnson & Johnson 1Q Results
20 May 2024 16:58 GMT
Breaking News
Innovative Medicine sales were up 1%, while COVID-19 Vaccine sales were down 97%.
05.20.24
Johnson & Johnson
1Q Revenues: $21.4 billion (+2%)
1Q Earnings: $5.4 billion (loss of $491 million 1Q23)
Comments: Innovative Medicine sales were …